All In Biotech

Drug Trial Radar · NCT07456033

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 Weeks

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 456 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

456

Planned (sponsor's estimate)

Start

Mar 13, 2026

Primary completion

Sep 23, 2030

Study completion Sep 23, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).

Conditions

  • Asthma

Interventions

  • DepemokimabDrug

    Depemokimab will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of clinically significant exacerbationsTime frame: Up to Week 156

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Little Rock, Arkansas · Recruiting

  • GSK Investigational Site

    Newport Beach, California · Recruiting

  • GSK Investigational Site

    Aurora, Colorado · Recruiting

  • GSK Investigational Site

    Aventura, Florida · Recruiting

  • GSK Investigational Site

    Kissimmee, Florida · Recruiting

  • GSK Investigational Site

    Lake Worth, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Shreveport, Louisiana · Recruiting

  • GSK Investigational Site

    Oklahoma City, Oklahoma · Recruiting

  • GSK Investigational Site

    DuBois, Pennsylvania · Recruiting

  • GSK Investigational Site

    Wyomissing, Pennsylvania · Recruiting

  • GSK Investigational Site

    Rapid City, South Dakota · Recruiting

  • GSK Investigational Site

    San Antonio, Texas · Recruiting

  • GSK Investigational Site

    Burke, Virginia · Recruiting

  • GSK Investigational Site

    Bradford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.